<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30197799</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Print">2095-3941</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>15</Volume>                    <Issue>3</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                    </PubDate>                </JournalIssue>                <Title>Cancer biology &amp; medicine</Title>                <ISOAbbreviation>Cancer Biol Med</ISOAbbreviation>            </Journal>            <ArticleTitle>Benefit of everolimus as a monotherapy for a refractory breast cancer patient bearing multiple genetic mutations in the PI3K/AKT/mTOR signaling pathway.</ArticleTitle>            <Pagination>                <MedlinePgn>314-321</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.20892/j.issn.2095-3941.2017.0188</ELocationID>            <Abstract>                <AbstractText>A postmenopausal patient with a diagnosis of estrogen receptor (ER) (+), progesterone receptor (PR) (+), and human epidermal growth factor receptor-2 (HER2) (-) breast cancer was reported. The patient refused surgery and was resistant to conventional chemotherapy regimens. Computed tomography and the circulating tumor cell test indicated that the patient's tumor burden increased rapidly even after several chemotherapy sessions. Multiple genetic aberrances in the phosphatidylinositol3-kinases (PI3K) signaling pathway were detected via next-generation sequencing (NGS)-based liquid biopsy, including a p. G1007R missense mutation in exon 21 of PIK3CA (33.61%), a p.L70fs frameshift mutation in exon 3 of phosphatase and tension homolog deleted on chromosome ten (PTEN) (49.14%), and a p. D1542Y missense mutation in exon 32 of mammalian target of rapamycin (mTOR) (1.66%). Therefore, only the mTOR inhibitor everolimus was administered to the patient. Partial remission (PR) was observed after 2 months, and sustained stable disease (SD) was observed after a year and a half. Subsequent sequencing showed that the mutation ratio of PIK3CA decreased to 4.17%, and that the PTEN and mTOR mutations disappeared, which revealed the significant curative effect of everolimus. We report the first case of successful monotherapy treatment using everolimus in a patient with advanced breast cancer bearing mutations in genes involved in the PI3K/ARK/mTOR signaling pathway. The success of this case highlights the invaluable clinical contribution of NGS-based liquid biopsy, as it successfully provided an optimal therapeutic target for the patient with advanced breast cancer.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Shi</LastName>                    <ForeName>Yehui</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Medical Oncology Department of Breast Cancer.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Wenwen</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>Cancer Molecular Diagnostics Core.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Immunology, Tianjin Medical University Cancer Institute &amp; Hospital, National Clinical Research Center forCancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin300060, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ye</LastName>                    <ForeName>Yingnan</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Cancer Molecular Diagnostics Core.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cheng</LastName>                    <ForeName>Yanan</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Cancer Molecular Diagnostics Core.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Han</LastName>                    <ForeName>Lei</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Cancer Molecular Diagnostics Core.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Liu</LastName>                    <ForeName>Pengpeng</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Cancer Molecular Diagnostics Core.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhao</LastName>                    <ForeName>Weipeng</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>Medical Oncology Department of Breast Cancer.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tong</LastName>                    <ForeName>Zhongsheng</ForeName>                    <Initials>Z</Initials>                    <AffiliationInfo>                        <Affiliation>Medical Oncology Department of Breast Cancer.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yu</LastName>                    <ForeName>Jinpu</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Cancer Molecular Diagnostics Core.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Immunology, Tianjin Medical University Cancer Institute &amp; Hospital, National Clinical Research Center forCancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin300060, China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>China</Country>            <MedlineTA>Cancer Biol Med</MedlineTA>            <NlmUniqueID>101588850</NlmUniqueID>            <ISSNLinking>2095-3941</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Biomed Res Int. 2013;2013:901578</RefSource>                <PMID Version="1">23957008</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2012 Feb 9;366(6):520-9</RefSource>                <PMID Version="1">22149876</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2012 Mar 8;366(10):883-892</RefSource>                <PMID Version="1">22397650</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Pathol. 2014 Sep;67(9):764-7</RefSource>                <PMID Version="1">25004944</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2017 Jan 1;28(1):34-43</RefSource>                <PMID Version="1">28177494</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2013 Oct 17;502(7471):333-339</RefSource>                <PMID Version="1">24132290</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer. 2006 Feb;42(3):290-4</RefSource>                <PMID Version="1">16376541</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nucleic Acids Res. 1989 Apr 11;17(7):2503-16</RefSource>                <PMID Version="1">2785681</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2002 Feb 1;20(3):719-26</RefSource>                <PMID Version="1">11821453</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Hematol Oncol. 2014 Jan 14;7:8</RefSource>                <PMID Version="1">24422672</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res. 2011;13(6):224</RefSource>                <PMID Version="1">22114931</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Genes Chromosomes Cancer. 2013 May;52(5):503-11</RefSource>                <PMID Version="1">23362162</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer Care (Engl). 2015 Nov;24(6):920-8</RefSource>                <PMID Version="1">25757548</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Adv Drug Deliv Rev. 2016 Oct 1;105(Pt A):3-19</RefSource>                <PMID Version="1">27089811</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2005 Oct 20;353(16):1673-84</RefSource>                <PMID Version="1">16236738</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Expert Opin Pharmacother. 2016 Jun;17(9):1189-96</RefSource>                <PMID Version="1">27052735</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2009 Jun 1;27(16):2630-7</RefSource>                <PMID Version="1">19380449</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Oncol. 2015 May;9(5):951-9</RefSource>                <PMID Version="1">25888066</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2016 Jun 15;22(12):2960-8</RefSource>                <PMID Version="1">26758560</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2016 Jun 1;22(11):2599-601</RefSource>                <PMID Version="1">26979397</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Genome Biol. 2017 Jul 21;18(1):136</RefSource>                <PMID Version="1">28732520</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2014 May 30;5(10):3012-22</RefSource>                <PMID Version="1">24931142</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Chemother Pharmacol. 2013 Apr;71(4):829-42</RefSource>                <PMID Version="1">23377372</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Discov. 2017 Jan;7(1):102-113</RefSource>                <PMID Version="1">27872130</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Anticancer Agents Med Chem. 2013 Mar;13(3):464-75</RefSource>                <PMID Version="1">22931419</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Chem. 2003 Jun;49(6 Pt 1):1028-9</RefSource>                <PMID Version="1">12766024</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2014 Apr;25(4):763-73</RefSource>                <PMID Version="1">24667713</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Clin Oncol. 2015 Dec;12(12):693-704</RefSource>                <PMID Version="1">26196250</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CA Cancer J Clin. 2015 Mar;65(2):87-108</RefSource>                <PMID Version="1">25651787</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2009 Oct 8;461(7265):809-13</RefSource>                <PMID Version="1">19812674</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2016 Jun 20;34(18):2115-24</RefSource>                <PMID Version="1">27091708</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Clin Oncol. 2013 Aug;10(8):472-84</RefSource>                <PMID Version="1">23836314</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Can J Gastroenterol Hepatol. 2018 Mar 7;2018:4248971</RefSource>                <PMID Version="1">29707525</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Histopathology. 2016 Nov;69(5):871-879</RefSource>                <PMID Version="1">27271096</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Pathologe. 2015 Nov;36(6):572-8</RefSource>                <PMID Version="1">26395890</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2008 Aug 9;372(9637):449-56</RefSource>                <PMID Version="1">18653228</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Genomics Inform. 2017 Mar;15(1):48-50</RefSource>                <PMID Version="1">28416949</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2001 Mar 15;344(11):783-92</RefSource>                <PMID Version="1">11248153</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2016 Jul 1;76(13):3989-4001</RefSource>                <PMID Version="1">27197157</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2016 Feb 10;34(5):419-26</RefSource>                <PMID Version="1">26503204</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Chin J Cancer Res. 2016 Feb;28(1):1-11</RefSource>                <PMID Version="1">27041922</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2017 Oct;18(10):1360-1372</RefSource>                <PMID Version="1">28800861</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Pathol. 2015 Feb;68(2):93-9</RefSource>                <PMID Version="1">25488926</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2012 Aug 1;30(22):2718-24</RefSource>                <PMID Version="1">22565002</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">PI3K/AKT/mTOR</Keyword>            <Keyword MajorTopicYN="N">everolimus</Keyword>            <Keyword MajorTopicYN="N">liquid biopsy</Keyword>            <Keyword MajorTopicYN="N">next-generation sequencing</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30197799</ArticleId>            <ArticleId IdType="doi">10.20892/j.issn.2095-3941.2017.0188</ArticleId>            <ArticleId IdType="pii">cbm-15-3-314</ArticleId>            <ArticleId IdType="pmc">PMC6121052</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>